Release issued 7th September 2006

Active Biotech publishes pre-clinical data regarding the TASQ prostate cancer project 2006-09-07 Active Biotech (ACTI.ST) publishes a new scientific paper - "Identification of ABR-215050 as lead second generation quinoline-3-carboxamide anti-angiogenic agent for the treatment of prostate cancer" - in the next issue of the scientific journal "Prostate" (pre-available as an e-publication at NCBI National Center for Biotechnology, http://www.ncbi.nlm.nih.gov/) in collaboration with Professor John T. Isaacs of Johns Hopkins University in Baltimore, USA.

The article summarizes pre-clinical data regarding Active Biotech's project TASQ for the treatment of prostate cancer.

The data verifies TASQ's anti-angiogenic activity i.e. inhibition of the growth of new blood vessels into the tumor, and is paralleled by an inhibition of tumor growth.

The objective for the company's TASQ project is to develop a pharmaceutical product that can be administered orally for the chronic treatment of prostate cancer.

Currently TASQ is in Phase I clinical trials in prostate cancer patients.

An interim evaluation of this study will be communicated separately within short.

Phase II/III studies are scheduled to commence in 2007.

Lund, September 7, 2006 Active Biotech AB (publ)

Sven Andréasson President & CEO

Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer immunotherapy with the primary indication non-small cell lung cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.

Active Biotech AB Box 724, SE-220 07 Lund Tel: +46 46-19 20 00 Fax: +46 46-19 20 50 www.activebiotech.com Enter the full press release here

(13th May 2008) Active Biotech advances ANYARA into Phase III clinical trial.

(15th April 2008) Preclinical data presented for Active Biotech's ANYARA technology

(24th October 2007) Active Biotech's Cancer Project ANYARA Proven Safe in Combination with Taxotere®

(10th August 2007) FDA Approves IND for Phase II Studies of TASQ

(26th July 2007) EMEA Grants Orphan Drug Status to Active Biotech's Cancer Treatment ANYARA